PharmaVOICE Editors' Blog
Tuesday, May 21, 2013
Monday, May 20, 2013
Driving Innovation in BioPharma: From Discovery to Delivery with Product Lifecycle Management
 |
| White Paper: Innovation in BioPharma |
Download this free white paper now.
This white paper explores how product lifecycle management (PLM) can enable biopharma companies to develop innovative products that generate real economic benefits for their organizations and health benefits for patients.
Provided by: Kalypso
Friday, May 17, 2013
Global Clinical Trial Data Collection: A minefield or a walk in the park?
 |
| Image by Chris Pearson |
Companies are losing clients and compromising their global clinical trials because the worldwide telephone numbers assigned to these trials are flawed. Participants and doctors calling to report critical trial data often cannot due to non-operational telephone numbers. The time and money spent to fix these faulty telephone numbers is costly, frustrating, and compromises the clinical trial and its success.
Provided by: Global Telecom Testing
Amped ATU:Free white paper How Data Fusion Can Turn Awareness, Trial, and Usage Studies Into a Powerful Tactical and Strategic Tool
 |
| Free white paper |
ATU studies can be turned into a powerful tactical and strategic tool by making them part of an integrated market research platform that includes a review of competitive promotional strategy, message recall and tracking, longitudinal patient data and prescription analysis, and benchmarking against normative data.
Provided by: Encuity Research
Thursday, May 9, 2013
Direct to Persona: The New DTC
 |
| DTC Marketing White Paper |
Download this free white paper now.
This whitepaper discusses the changes in Direct to Consumer marketing that are on the horizon. The old model worked for a while, but to thrive in DTC today a more social media marketing approach is needed. The new model is flexible, direct, and can be tracked in real time with. An integrated social media approach delivers better results with Direct to Persona marketing.
Provided by: Liquid Grids
Thursday, May 2, 2013
What is Creativity?
 |
| Anthony Rotolo |
Thought Leader:
Anthony Rotolo, Chief Creative Officer, True Health + Wellness
Download Podcast
Download Podcast Transcript
See All PharmaVOICE Podcasts
See All PharmaVOICE White Papers
Wednesday, May 1, 2013
Developing Robust Potency Assays for Validation
 |
| Dr. Peter Wunderli |
Thought Leader:
Peter Wunderli, Ph.D., Associate Director, Biopharmaceutical Services at PPD
Download Podcast
Download Podcast Transcript
Download Related White Paper
See All PharmaVOICE Podcasts
See All PharmaVOICE White Papers
Development and Qualification of Potency Assay Methods to Support Early Phase Release and Stability Testing of a Biotherapeutic Formulated with a Bioresorbable Carrier
Download this free white paper now.
PPD's Cell Based Assay Laboratory was contracted by a client to improve the performance of a potency assay that had been developed for their biological product. The assay met pre-established qualification specifications for linearity, precision, and specificity and has been successfully implemented in testing the release and stability of multiple product lots, across an 18 month testing period.
Provided by: PPD
Tuesday, April 30, 2013
New Challenges for Global Clinical Trials: Managing Supply Logistics in an Expanding Clinical Trial Universe
 |
| Global clinical trials require appropriate communication |
This white paper provides an overview of the New Challenges for Global Clinical Trials. The specific challenges discussed are the changing regulatory environment, customs requirements, infrastructure issues, data management, regional idosyncrasies, and differing quality standards.
Provided by: Fisher Clinical Services
Monday, April 29, 2013
Upcoming Webinar: Prevention of Persistent Atrial Fibrillation – the Next Frontier in Pharmacotherapy
 |
| Register for this webinar today |
Thursday – May 30, 2013 / 11:00 am – 12:00 pm EST – Free Attendance
Sponsored by avertAF
The webinar will introduce the unmet need and pharmaceutical opportunity for pharmacological prevention of persistent atrial fibrillation. Professor Camm will put our discoveries and plans against the backdrop of recent advances in management of atrial fibrillation. Our focus is to enable cost-effective industry development of the first generation of disease modifying agents that aim to prevent the more serious forms of atrial fibrillation.
Register today!
During the webinar, we’ll discuss:
- Current treatment objectives in atrial fibrillation
- Unmet need in management of AF
- Research findings on the role of remodeling in development of AF
- Research findings related to role of galectin-3 and other targets
- avertAF research objectives and plan
- avertAF model and benefits to participating companies
- Atrial fibrillation is a common and serious arrhythmia
- Recent pharmaceutical focus has been on prevention of complications
- Animal studies point to structural and electric remodeling as important processes
- These processes appear to be galectin-3 mediated
- Blocking the remodeling pathway can prevent AF
- avertAF is an open industry initiative
- avertAF aims to facilitate drug development for AF prevention
- Cardiovascular drug research and development
- Business development
- Strategy
Bertram Pitt, MD
Professor Emeritus
University of Michigan
John Camm, QHP, MD
BHF Professor of clinical cardiology
St George’s University, London, and Imperial University, UK
José Jalife, MD
Cyrus and Jane Farrehi Professor of Cardiovascular Research
University of Michigan
Pieter Muntendam, MD
President
avertAF
Register today!
Full webinar info
Subscribe to:
Posts (Atom)
Posts
